
(HealthDay News) – Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer’s patients enrolled in clinical trials of the drug. Approved amid controversy last year by the U.S. Food and Drug Administration, the latest decision was meant to protect patients while gathering more clinical data on whether… read on > read on >